Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

4.25
-0.0900-2.07%
Post-market: 4.250.00000.00%19:30 EDT
Volume:4.32M
Turnover:18.13M
Market Cap:366.40M
PE:-1.13
High:4.40
Open:4.32
Low:4.10
Close:4.34
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.49
T/O Rate:7.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.20
PE(LYR):-1.34

Loading ...

Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated

TIPRANKS
·
Jul 06

Eyepoint Chief Medical Officer Ramiro Ribeiro Disposes of 4,875 Common Shares Worth $73,167.95

Reuters
·
Jul 03

Eyepoint Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 01

Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating

MT Newswires Live
·
Jul 01

EyePoint price target raised to $65 from $29 at Chardan

TIPRANKS
·
Jul 01

Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 25

Eyepoint Pharmaceuticals Price Target Maintained with a $68.00/share by Guggenheim

Dow Jones
·
Jun 24

Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 24

EyePoint shareholders approve 4.9 million-share increase to 2023 incentive plan

Reuters
·
Jun 22

EyePoint grants inducement stock options for 39,700 shares at $12.08 each

Reuters
·
Jun 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 16

Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43

TIPRANKS
·
Jun 12

EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease

TIPRANKS
·
Jun 04

Phase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)

Simply Wall St.
·
May 22

EyePoint Pharma Bets Big on DURAVYU Pivotal Data

TIPRANKS
·
May 20

EyePoint management joins Stifel Virtual Ophthalmology Forum fireside chat

Reuters
·
May 19

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
May 19

EyePoint grants inducement stock options for 158,100 shares at $12.35 each

Reuters
·
May 18

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 18